Article info

Download PDFPDF

2022-RA-1504-ESGO Tamoxifen-megestrol acetate combination hormonal therapy is an effective fertility-sparing treatment in early-stage endometrial cancer patients who have failed progestin only hormonal therapy
Free

Authors

Citation

Lim H, Lee SJ, Lee S, et al
2022-RA-1504-ESGO Tamoxifen-megestrol acetate combination hormonal therapy is an effective fertility-sparing treatment in early-stage endometrial cancer patients who have failed progestin only hormonal therapy

Publication history

  • First published October 20, 2022.
Online issue publication 
October 27, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.